ANGLE plc: Angle PLC- Ovarian Cancer Study Patient Enrolment Completed
Headline results from the Study expected in Q4 2021
Study designed to support launch of an ovarian cancer test from ANGLE's clinical laboratories in the United States and the UK
GUILDFORD, SURREY, UK / ACCESSWIRE / April 26, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that its 200 patient ovarian cancer clinical verification study ("the Study") has completed patient enrolment.
The Study, undertaken by the University of Rochester Medical Center Wilmot Cancer Institute, New York, USA (URMC), is designed to evaluate the use of ANGLE's Parsortix
® system for circulating tumour cell (CTC) harvest and subsequent downstream analysis with ANGLE's HyCEAD multiplex RNA platform as a simple blood test to detect the presence of ovarian cancer in women with a pelvic mass prior to surgery.